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OUTCOMES AFTER CD34+ SELECTION WITH OR WITHOUT THE ADDI-
TION OF PHOTO-ALLODEPLETED T LYMPHOCYTES IN MYELOABLATIVE
HLA-MATCHED SIBLING TRANSPLANTATION
Battiwalla, M.1, McIver, Z.1, Klotz, J.1, Draper, D.1, Haggerty, J.1,
Chawla, K.1, Superata, J.1, Stroncek, D.2, Khuu, H.2, Citrin, D.3,
Sabatino, M.2, Leitman, S.2, Ito, S.1, Barrett, J.1 1NHLBI, NIH, Be-
thesda, MD; 2CC, NIH, Bethesda, MD; 3CCR, NCI, Bethesda, MD
Introduction: Photodepletion (PD) is a method to selectively de-
plete alloreactive lymphocytes from the graft to reduce graft versus
host disease (GVHD) in allogeneic stem cell transplantation. We
have previously reported results with PD and shown a low rate of re-
lapse without significant GVHD (Mielke, et al. and McIver, et al.
BBMT2011). In this retrospective analysis, we compared transplants
using photodepleted donor lymphocytes (n 5 24) with a similar co-
hort of T cell depleted (TCD) transplants (n 5 48).
Methods: All subjects received myeloablative conditioning with cy-
clophosphamide (120 mg/kg), fludarabine (125mg/m 2) and TBI (12
Gy, or 4 Gy for age $55). Peripheral blood stem cells were CD34+
selected by the Miltenyi CliniMacs system, with infusion of a target
CD34+ dose of 6 x 106/kg (range 3-10 x 106/kg) and a CD3+ dose of
\5 x 104 /kg. All patients received cyclosporine as the only GVHD
prophylaxis. The PD cohort received 5 x106/kg PD donor lympho-
cytes at day 0 while the TCD cohort received an unmanipulatedDLI
of 5 x106 CD3+/kg on day 90.
Results: Seventy-two patients underwent HLA-identical sibling
transplant. The median age was 43 years (range 16-68), 50% were
males. Transplant indications were AML (29), ALL (17), bipheno-
typic acute leukemia (2), MDS/MPD (15), CML (3), NHL/CLL
(6). Baseline characteristics were similar apart from a greater propor-
tion of high risk patients in the PD cohort (66% vs 50%).
The time to ANC .0.5 x 109/L and the time to complete donor
myeloid chimerism (median, day 14) were similar in both groups,
but PD transplants achieved earlier complete donor T-lymphocyte
engraftment (31 vs 45 days, p 5 0.01). Primary engraftment failure
was seen in 3 patients receiving TCD versus none in the PD cohort.
There were no significant differences in other clinical outcomes. The
cumulative incidence of acute grades II-IV GVHD, III-IV GVHD,
chronic-limited GVHD and chronic-extensive GVHDwere 50% vs
46%, 13% vs 18%, 39% vs 12% and 26% vs 33% respectively, in PD
vs TCD cohorts. With a median follow up of 2.8 years, Kaplan-Me-
ier estimates of overall survival, relapse and nonrelapse mortality
were 44%, 28% and 46% respectively for PD and 49%, 25% and
35% for TCD.
Conclusions: This comparison shows that the addition of 5x106/kg
photodepleted donor lymphocytes at day 0 to a CD34+ selected pe-
ripheral stem cell graft results in superior engraftment, equivalent
low rates of GVHD and equivalent disease control in HLA-matched
sibling transplantation.152
GRANULOCYTE TRANSFUSIONS IN A PATIENT WITH APLASTIC ANEMIA
SUFFERING FROM LIFE-THREATENING FUNGAL INFECTION – GAPPING
FOR HEMATOPOIETIC CELL TRANSPLANTATION
Bitan, M., Levin, D., Dvir, R., Sayar, D., Manistersky, M., Achituv, S.,
Rosenfeld-Kedar, H., Elhasid, R. Tel-Aviv Sourasky Medical Center, Te-
l-Aviv, Israel
Background: Acquired aplastic anemia (AA) is the most common
form of bone marrow failure. It is a life-threatening condition ac-
companied by severe infections, including several fungal specious.
Among these, fusarium is emerging pathogen in immunocomprom-
ized patients, particularly those with severe and prolonged neutrope-
nia. Allogeneic hematopoietic cell transplantation (HCT) is the
treatment of choice for AA in patients with matched sibling donor.Patient andMethods:One year old child was diagnosed as suffering
from acquired AA. Due to lack of matched related donor, he received
treatment with cyclosporine-A and anti-thymocytic globulin (ATG).
While being neutropenic, he developed disseminated life-threaten-
ing fusarium fungal infection including positive blood culture, mul-
tiple skin lesions and osteomyelitis. The patient received
amphotericin-B with no clinical improvement and general deteriora-
tion. In order to save the patient’s life and prepare him for future
transplant, he received 12 granulocyte transfusions over a period of
3 months. Granulocytes were harvested from adult volunteers using
granulocyte-colony-stimulating-factor (G-CSF) and dexametha-
sone. Every harvest was divided into 2 doses given every 12 hours.
Results: Skin lesions disappeared, blood cultures became negative
and osteomyelitis resolved during granulocyte transfusions. By that
time a new sibling was born, from whom cord blood was harvested
and HLA examination revealed matched sibling donor. Since the fu-
sarium disseminated infection was controlled the patient was able to
undergo allogeneic HCT using ATG (Fresenius, 5mg/kg/day for 5
days) and cyclophosphamide (50mg/kg/day for 4 days) as condition-
ing regimen. Neutrophil engraftment occurred on day +14 with do-
nor chimerism between 80-90%. No veno-oclusive-disease (VOD)
or graft-versus-host-disease (GVHD) was demonstrated. He is cur-
rently 140 days post transplant alive andwell with no evidence for the
fusarium infection.
Conclusions: Granulocyte transfusions by G-CSF-stimulated do-
nors while waiting HCT should be considered in patients suffering
from life-threatening fungal infections.153
Stemex® IS EXPANDING: PIVOTAL TRIAL NEARS COMPLETION, AND
DEVELOPMENT OF A CRYOPRESERVED PRODUCT IS UNDERWAY
Snyder, D., Landau, E., Rosenheimer, N.G., Mandel, J., Glukhman, E.,
Hasson, N., Lador, C., Olesinski, E., Hagler-Price, G., Leshem, A.,
Freind, E., Ben Abu, K., Sharabi, S., Shachaf, O., Israeli, H.,
Harati, D., Srur-Kidron, O., Galamidi Cohen, E., Peled, T. Gamida
Cell Ltd., Jerusalem, Israel
Cord blood transplantation (CBT) is limited by low number of
TNC and CD34+ cells, influencing the incidence and rate of hema-
topoietic recovery and risk of early transplant-related mortality. Ex
vivo expansion is a strategy to increase the number of progenitor cells
and improve clinical outcomes. Several early stage studies are evalu-
ating the clinical benefit of expansion, mainly in a double CBT con-
figuration. The StemEx trial evaluates the potential contribution
of expansion in a single CBT configuration. StemEx is manufactured
from a portion of a single CBU, originally frozen in 2 separate frac-
tions. CD133+ progenitor cells, purified from the smaller or equal
fraction, are cultured for 21-23 days with cytokines and a copper che-
lator, TEPA, which delays differentiation and promotes expansion of
progenitor cells with engraftment capabilities. A global pivotal reg-
istration study evaluating the safety and efficacy of StemEx in pa-
tients with hematological malignancies following myeloablative
treatment is currently completing recruitment. Safety and efficacy
outcomes of the study will be available in 2012. To date, 82 of 88 Ste-
mEx batches manufactured in 3 centralized GMP facilities, have
been successfully expanded: median fold expansion of TNC,
CD34+ cells and CFU over culture input were 399 (range 52-764),
75 (6-280) and 107 (43-662), respectively. Expansion of only a por-
tion of the CBU resulted in a median 8.4 fold increase (0.8-90.3)
in the number of CD34+ cells infused over the number that would
be infused from the entire CBUwithout expansion. TheCFUpoten-
tial of culture seeded CD133+ cells measured at day-0 of production
indicates the expansion potential of the cryopreserved CB cells. In all
six batches which failed to expand, day-0 CFU was low, while day-
0 CFU of all successfully expanded batches was within specification
ranges. This information, available before patient myeloablation,
strengthens the clinical applicability of StemEx. All StemEx batches
were successfully delivered and infused. We are currently in the last
stages of development of a frozen StemEx product. The added flex-
ibility in the timing of transplantation allows for changes resulting
from patient disease progression or complications. With the chal-
lenges of an ex vivo expanded product being successfully met in
the current registration trial, and the development of a frozen
Poster Session I S261product, StemEx demonstrates its feasibility as a quality alternative
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MORE ACCURATE DETERMINATION OF BLOOD VOLUME ALLOWS FOR
A HIGH CORRELATION OF PRE-APHERESIS PERIPHERAL BLOOD AND FI-
NAL APHERESIS PRODUCT CD34+ CELL COUNTS
Parker, B.1, Hastings, J.2, Folkert, J.2, Nagy, G.2, Bachier, C.1,
LeMaistre, C.F.1, Shaughnessy, P.J.1 1Texas Transplant Institute, San
Antonio, TX; 2Methodist Hospital, San Antonio, TX
The final apheresis product CD34+ cell count is used to determine
if more apheresis procedures are necessary to collect sufficient hema-
topoietic stem cells for autologous (auto) peripheral blood stem cell
transplantation. Flow cytometric analysis of CD34+ cells can take
several hours. A more timely way to predict apheresis product
CD34+ cell counts may help determine if further cytokines are nec-
essary or if apheresis catheters can be removed, and improve the ef-
ficiency of patient (pt) care. We performed a retrospective review of
all pts undergoing auto peripheral blood (PB) stem cell mobilization
with G-CSF alone, G-CSF and plerixafor, or with chemotherapy
(chemo) followed by G-CSF, from July 2010 through May 2011
who underwent PB stem cell collection on the COBE Spectra cell
separator. Linear regression models were used to formulate pt blood
volume (BV) based on the pre-apheresis CD34+ cell count per micro
liter of blood, the final apheresis product CD34+ cell counts, and the
amount of blood processed during the apheresis procedure. This cal-
culated BV is expressed by the formula BV5 82.5(pts weight in Kg)
+ 793.We then prospectively evaluated the next consecutive pts who
underwent stem cell mobilization and apheresis in June and July
2011. Twenty-seven apheresis collections were done on 26 pts.
The PB CD34+ cell count/ul was multiplied by 1000 and this prod-
uct was multiplied by the calculated BV and then divided by the pts
weight [(PBCD34+ cell count x 1000) x BV]/Kg to determine the
predicted apheresis product CD34+ cell count, which was then com-
pared to the actual apheresis product final CD34+ cell count. On the
first day of collection the mean for the predicted product CD34+ cell
count was 4.98 x 106 +/- 3.1 x 106, and the actual apheresis product
CD34+ cell count was 4.61 x 106 +/- 2.90 x 106 (Pearson correlation r
value of 0.913 and a p value\0.001). There was no significant differ-
ence in the correlation between pts mobilized with G-CSF alone, G-
CSF and plerixafor or after chemo and G-CSF. In conclusion,
a more accurate determination of pt BV allowed for a high degree
of correlation on the first day of PB stem cell collection between
the predicted product CD34+ cell count and the actual apheresis
product CD34+ cell count. An accurate prediction of the final apher-
esis product CD34+ cell count may allow for less cytokine use,
quicker removal of catheters, and more efficient disposition of
patients.155
CXCL12 G801A POLYMORPHISMS DO NOT PREDICT RESPONSE TO
MOBILIZATION BY PLERIXAFOR IN NORMAL ALLOGENEIC STEM CELL
DONORS
Schroeder, M.A.1, Rettig, M.P.1, Uy, G.L.1, Lopez, S.1, Trinkhaus, K.2,
Graubert, T.A.1, DiPersio, J.F.1 1Washington University School of Med-
icine, Saint Louis, MO; 2WashingtonUniversity School of Medicine, Saint
Louis, MO
Several reports suggest that G/A transition at position
801(G801A) in the 3’ untranslated region (3’UTR) of CXCL12 in
donors mobilized with G-CSF can predict for response to mobiliza-
tion. It is unknown if this polymorphism impacts mobilization with
the CXCR4 antagonist plerixafor. We hypothesized that the AA
polymorphism would show increased stem cell mobilization in re-
sponse to plerixafor.
Methods: A cohort of 55 donors enrolled in a phase I/II clinical trial
evaluating IV plerixafor mobilization were evaluated. 21 donors inthe phase I portion were mobilized with IV plerixafor at increasing
doses (0.08, 0.16, 0.24, 0.32, 0.40, 0.48mg/kg) in a 3+3 design fol-
lowed by one week wash out then mobilization and apheresis collec-
tionwith 0.32mg/kg subcutaneous plerixafor. 34 donors in the phase
II portion of the trial were mobilized with 0.32mg/kg plerixafor IV.
The G801A polymorphism in the 3’UTR of the CXCL12 gene was
analyzed in peripheral bloodmononuclear cells isolated from phase I
and II donors. Final collected CD34/Kg recipient weight on day 1,
CD34/liter apheresis on day 1, and reaching goal collection of
.2x10e6CD34/kg recipient weight were used as the dependent vari-
ables in determining mean differences based on genotype and for
univariate analysis.
Results: A total of 55 allogeneic donors were mobilized (female/
male 5 25/30; age range 12 – 67 years, median 50 years). In total
54 were evaluable for genotyping. The frequency of genotypes in
the combined cohort of 54 individuals was: GG 5 38(69.1%), AG
5 14(25.5%), AA 5 2(3.6%). There was no detectable difference
in themean number of CD34 cells/L apheresis on day 1 of collection
by CXCL12 genotype (p5 0.78, ANOVA, CD34/liter log10 scale).
Mean CD34 cells/L apheresis (log10 scale) was: GG 5 7.021 (95%
CI 6.936, 7.107), AG 5 7.028 (95%CI 6.883, 7.172), AA 5 6.892
(95%CI 6.524, 7.260). The probability of collecting at least
2x10e6 CD34 cells/Kg recipient weight on day 1 was not affected
by CXCL12 genotype (logistic regression, p 5 0.74). The propor-
tion of patients with a successful collection on day 1 in each group
was: GG 5 64.86 (95%CI 47.46, 79.79), AG 5 53.85 (95%CI
25.13, 80.78), AA 5 50 (95% CI 1.26, 98.74).
Conclusion: These results suggest that unlike what has been re-
ported for normal allogeneic stem cell donors mobilized with G-
CSF, plerixafor mobilization yield is not affected by the CXCL12
3’UTR G801A polymorphism.156
RELATIONSHIPS AMONG COMMONLY USED MEASURES OF CORD BLOOD
POTENCY, ALDHBR CELL CONTENT, AND COLONY FORMING CELL CON-
TENT IN CORDBLOODUNITS PRIOR TO CRYOPRESERVATION: TOWARDS
AN IMPROVED METRIC FOR POTENCY OF BANKED CORD BLOOD
Page, K.1, Betz-Stablein, B.2, Mendizabal, A.2, Wease, S.2, Shoulars, K.1,
Gentry, T.1, Balber, A.E.3, Kurtzberg, J.1 1Duke University, Durham,
NC; 2The EMMES Corporation, Rockville, MD; 3Cicada Biopharma-
ceutical Consulting, Durham, NC
Despite adequate total nucleated cell (TNC) dosing, engraft-
ment delays and failures remain a significant issue for patients un-
dergoing cord blood (CB) transplantation. We have shown before
that post-thaw colony forming units (CFU) better predicted en-
graftment compared to TNC and CD34+. However, the CFU as-
say is not standardized and results take weeks. Aldehyde
dehydrogenase (ALDH), an enzyme expressed in stem and pro-
genitor cells (ALDHbr cells), is detected by a rapid functional,
flow-based intracellular assay. In this study, we explored statistical
relationships among TNC, mononuclear cell count (MNC),
CD34+, ALDHbr cells and CFU in a large cohort of fresh CB
units (CBU) prior to cryopreservation. Our ultimate goal is to
identify the best parameter(s) to predict potency as defined by suc-
cessful engraftment.
Methods: Post-processed TNC, MNC, CD34+ and CFU content
were routinely enumerated on fresh CBUs donated to the Carolinas
Cord Blood Bank for public (n5 5268) or directed use (n5 14) from
9/07-7/09. Aldecount (Aldagen, Inc) was used to measure
ALDHbr content. Statistical relationships were established.
Results: The median TNC, CD34+, MNC, ALDHbr and CFU
content were: 11.8x108(range, 2.9-55.5x108), 3.36 x106(range,
0.17-98.2x106), 5.5x108(range, 1.7-20.0x108), 4.3x 106(0-36.6x106)
and 34.0x105(range, 0.6-193.3x105), respectively. Significant corre-
lations existed among measured parameters (Table 1). By stan-
dardizing univariate models, we were able to rank using AIC values.
CFUwas best predicted byTNC (AIC5 11,501) followed closely by
ALDHbr (AIC 5 12,012) and, to a lesser degree, MNC (AIC 5
12,412) and CD34+ (AIC 5 12,612). Multivariate results were
similar (data not shown). Ratios of ALDHbr and CD34+ to CFU
were 1.36:1 and 1.09:1, respectively, whereas the ratio of TNC to
CFU was 332:1.
